BOCOM International Holdings Company Sticks to Its Buy Rating for Simcere Pharmaceutical Group Limited (2096)Tip Ranks·1 day ago, 03:45 AM02096-0.78%
Simcere Pharmaceutical grants 795,000 RSUs under 2021 share award schemePUBT·Aug 21 at 05:45 AM02096-0.78%
Simcere Pharmaceutical Delivers Double-Digit Growth on Innovative Drug MomentumTip Ranks·Aug 20 at 10:08 AM02096-0.78%
Simcere Launches RMB1 Billion Share Buyback to Signal Confidence in OutlookTip Ranks·Aug 20 at 10:08 AM02096-0.78%
Simcere Pharmaceutical files board, committee member list with disclosure responsibilitiesPUBT·Aug 20 at 09:55 AM02096-0.78%
Simcere Pharmaceutical launches open-market share buyback of up to RMB 1 billionPUBT·Aug 20 at 09:53 AM02096-0.78%
Simcere Pharma sets board meeting to review interim results, consider dividendPUBT·Aug 10 at 05:59 AM02096-0.78%
Huatai Securities Sticks to Their Buy Rating for Simcere Pharmaceutical Group Limited (2096)Tip Ranks·Aug 2 at 12:25 AM02096-0.78%
Simcere SANBEXIN added to China 2026 National Essential Medicines ListPUBT·Jul 9 at 07:01 AM02096-0.78%
Simcere Pharmaceutical Group Limited (2096) Receives a Buy from UBSTip Ranks·Jun 29 at 05:15 AM02096-0.78%
Biren Amin Initiates Buy on Rademikibart Developer with Overweight Rating and DCF-Based $7 Price Target on Differentiated Asthma/COPD OpportunityTip Ranks·Jun 26 at 05:05 AMCNTB-1.24%02096-0.78%
